View Item 

Show simple item record

Natural antibody to a human bladder carcinoma cell line
dc.contributor.authorGrossman, H. Bartonen_US
dc.date.accessioned2006-09-11T18:16:45Z
dc.date.available2006-09-11T18:16:45Z
dc.date.issued1982-08en_US
dc.identifier.citationGrossman, H. Barton; (1982). "Natural antibody to a human bladder carcinoma cell line." Cancer Immunology Immunotherapy 13(2): 89-92. <http://hdl.handle.net/2027.42/46849>en_US
dc.identifier.issn1432-0851en_US
dc.identifier.issn0340-7004en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46849
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7159876&dopt=citationen_US
dc.description.abstractSera from 144 healthy blood donors were screened for the presence of antibody against the bladder carcinoma cell line RT4 by means of an immune adherence assay. Only one serum (9241) demonstrated high activity with a titer of 1/124. Qualitative and quantitative absorption analyses were carried out with a wide variety of cells to characterize the specificity of the reaction. Cells used for absorption were both cultured and non-cultured and normal and malignant. The reactivity was absorbed by the bladder cancer cell lines RT4 and 5637 and the lung cancer cell line SK-LC-LL. In addition, surgically obtained urothelium from a patient with transitional cell carcinoma abrogated reactivity. No other absorbing cells removed the reactivity of serum 9241 for RT4. The antigen defined by this serologic reaction is heat-stable and trypsin-resistant, as demonstrated by using heated or trypsinized RT4 cells for absorption.en_US
dc.format.extent420628 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherOncologyen_US
dc.subject.otherCancer Researchen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherImmunologyen_US
dc.titleNatural antibody to a human bladder carcinoma cell lineen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMicrobiology and Immunologyen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Surgery, Section of Urology, University of Michigan Medical Center, 48109, Ann Arbor, MI, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid7159876en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46849/1/262_2004_Article_BF00205306.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00205306en_US
dc.identifier.sourceCancer Immunology Immunotherapyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
262_2004_Article_BF00205306.pdf
Size:
410.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.